The healthcare systems in Germany and the United Kingdom are examples of systems that are able to manage costs while improving access to medications; however, it is unlikely that the US will follow these models, explained Gerard Anderson, PhD, of Johns Hopkins Bloomberg School of Public Health.
Transcript (slightly modified)
What is being done in other countries to improve access to medications? Can the US use these as a model?
There are a lot of things that we could do, but very few things that we probably will do. There are 2 systems that we really should take a look at very closely. The first one is in the UK and it’s called NICE, and the second one is in Germany—they’re similar, but different.
The easiest one to understand is NICE in the UK, and what they do is they say if a drug, or if a device, costs more than about $40,000 per quality-adjusted life year—a poor life year, to make it a little simpler—they will pay for it. If you charge more than that, we’re not going to buy it. Now a drug company knows, "well, if I price it at $39,999, I’m going to get it covered, and if I price it at $50,000, I’m not going to get it covered." So, you’ve told them exactly what they’re going to do.
Germany does something very similar to that, but not exactly the same. It makes some more adjustments for the type of disease that you have. It essentially says if you have cancer, or something like that, we might pay a little bit more than if you have diabetes. It’s all based upon, historically, how much we spend for that particular drug to treat you.
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna
January 25th 2025Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
Read More